The Effect Of Dasatinib On DCs And The Preparation Of Dasatinib And An Antigen Peptide Co-loaded Nano-vaccine

Objective:To prepared a Melan-A(aa26-35*A27L)analogues(P peptides)and dasatinib co-loaded novel niosome vaccine for providing a potential treatment strategy for the therapy of multiple myeloma(MM).Methods:(1)The effect of dasatinib on the expression of maturation associated surface biomarkers of dentritic cells(DCs)was investigated by flow cytometry,and the effect of dasatinib on cytokines and chemokines secreted by DCs was analyzed by ELISA method.(2)P peptide and dasatinib co-loaded niosome(P peptide/dasatinib-niosome)was prepared by thin film hydration method combined with ultrasonic probe,and then it was characterized.Results:(1)Dasatinib with the concentration of 25nM enhanced the expression of CD40 and HLA-DR on HD-derived DCs and enhanced the expression of CD40,CD83 and HLA-DR on CML patient-derived DCs.However,dasatinib had no effect on the levels of cytokine and chemokine secreted by DCs.(2)The optimal formulation and preparation method for P peptide/dasatinib-niosome were determined by the orthogonal experiment.The co-loaded niosome vaccine was finally prepared.The average encapsulation efficiency of P peptide was(74.14±0.16)%,and that of dasatinib was(68.06±0.10)%.The average particle size was(133.05±1.33)nm,the average PDI was(22.79±0.93)%,and the average Zeta potential was-22.66±0.67.The niosome vaccine showed good physical stability when storage for 10 days at 4℃.Conclusion:Dasatinib promotes the maturation of DCs,suggesting that it can be a DCs adjuvant to be applied in DCs-based therapies such as DCs vaccines.The P peptide/dasatinib-niosome novel vaccine has been successfully prepared,which show high encapsulation efficiency of cargos and good stability.